ARCHIVES

Progression-free survival as a primary endpoint for drug approval requires prospective planning, FDA’s Pazdur says.

This article is from The Cancer Letter archive.

Vol. 30 No. 19 | May 7, 2004

Download PDF Visit The Full Archive

Related Articles

Low-Dose Warfarin Prevents Blood Clots, NIH Study Finds

February 28, 2003

NCI Details How Year 2000 Goals Can Be Reached Bypass Budget Spells Out How Much It Will Cost

June 8, 1984

Daschle Nomination For HHS Secretary Held Up in Senate Finance Committee; Corr Nominated Deputy HHS Secretary

January 16, 2009

In Brief: Griesemer Returns To NIEHS to Head Toxicology Research & Testing; Robert Burnight Dies at 69

August 12, 1988

Two Breast Cancer Treatments Show Similar Benefit In Trial

December 30, 2005

Center Directors, NCI Staff Agree- They Have Problems

November 26, 1976